NeurologyLive® Friday 5 — January 24, 2024

Author(s):

Key Takeaways

Anticipated FDA decisions in 2025 could significantly impact neurology, with approvals that researchers and clinicians should monitor closely.
Establishing entrustable professional activities for neurocritical care APPs is crucial for standardizing practices and enhancing care quality.
The brain microbiome's interaction with immune responses may contribute to Alzheimer's disease, offering new research avenues.
Responsive neurostimulators could shorten drug evaluation timelines and improve epilepsy treatment, advancing drug development.
Recent preclinical studies on neuropilin-1 enhance understanding of its role in chronic pain, potentially guiding future therapeutic strategies.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending January 24, 2024.

Welcome to NeurologyLive^®'s Friday 5! Every week, the staff compiles 5 highlights of NeurologyLive^®'s widespread coverage in neurology, ranging from newsworthy study findings and FDA action to expert interviews and peer-to-peer panel discussions.

1: Pending FDA Decisions in Neurology to Watch in the First Half of 2025

Take a look at some of the most-anticipated FDA pending approvals expected in 2025 that researchers and clinicians in neurology should keep an eye out on.

2: Establishing Entrustable Professional Activities for Neurocritical Care APPs: Daniel Harrison, MD

The neurointensivist and assistant professor of neurology at Boston Medical Center provided insight on a 2024 paper that defined consensus entrustable professional activities for neurocritical care advanced practice providers. [WATCH TIME: 5 minutes]

3: Exploring the Role of Viruses and Immune Responses in Alzheimer Disease: Or Shemesh, PhD

The assistant professor at The Hebrew University of Jerusalem School of Pharmacy discussed how the brain microbiome may contribute to Alzheimer through interactions with immune responses and proteins. [WATCH TIME: 5 minutes]

4: NeuroVoices: Jacqueline A. French, MD, on Leveraging Neurostimulators to Advance Epilepsy Drug Development

The professor of neurology at NYU Grossman School of Medicine talked about using responsive neurostimulators to seek shortened drug evaluation timelines and enhance epilepsy treatment.

5: Expanding Knowledge on the Role of Neuropilin-1 in Chronic Pain: Nigel Bunnett, PhD, BSc

The professor and chair of the Department of Molecular Pathobiology at NYU College of Dentistry discussed how a recently published preclinical study adds to the understanding of neuropilin-1 in chronic pain. [WATCH TIME: 3 minutes]